ClinicalTrials.gg

Program

comtifator

Also written as “BMS-986419”, “BMS-986419 DR Capsule” and “BMS-986419 IR Tablet”.

Its studies are led by Bristol-Myers Squibb.

Furthest: phase 1, since Apr 27, 20234 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb40 open or runningphase 1since Apr 27, 2023Apr 27, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 27, 2023First study: phase 1 study in Healthy VolunteersFirst studyNCT05847439 · 8 enrolled · United States
  2. Jun 27, 2023Phase 1 study in Healthy VolunteersNCT05932277 · 22 enrolled · United States
  3. Jul 20, 2023Phase 1 study in Healthy VolunteersNCT05963932 · 60 enrolled · United States
  4. Feb 21, 2025Phase 1 study in Healthy VolunteersNCT06846866 · 74 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06846866Healthy Volunteers · United States1CompletedOct 21, 202574
NCT05963932Healthy Volunteers · United States1CompletedOct 17, 202360
NCT05932277Healthy Volunteers · United States1CompletedSep 13, 202322
NCT05847439Healthy Volunteers · United States1CompletedJul 5, 20238

How it is read

Names in the registry

  • “BMS-986419”, 2 entries
  • “BMS-986419 DR Capsule”, 1 entry
  • “BMS-986419 IR Tablet”, 1 entry
  • “[14C]BMS-986419”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.